Le Lézard
Classified in: Health
Subject: MRR

Interstitial cystitis (IC) drugs market size to increase by USD 369.58 million: Analysis of major players as well as the key contributor region - Technavio


North America will account for 35% of the global interstitial cystitis (IC) drugs market

NEW YORK, Jan. 30, 2023 /PRNewswire/ -- North America will account for 35% of the global Interstitial cystitis (IC) drugs market growth. The increasing cases of interstitial cystitis and the rise in research funding are driving the growth of the regional market. The Interstitial Cystitis Drugs Market by Type, Distribution Channel, and Geography - Forecast and Analysis 2023-2027 report has been published by Technavio. Market growth is estimated to accelerate at a CAGR of 5.9% and register an incremental growth of USD 369.58 million during the forecast period. The report provides a comprehensive analysis of growth opportunities at regional levels, new product launches, the latest trends, and the post-pandemic recovery of the global market. Download a PDF Sample Report

Company Profiles

The interstitial cystitis (IC) drugs market report includes information on the key products and recent developments of leading vendors, including:

Market Dynamics

The market is driven by factors such as the high prevalence of interstitial cystitis, increasing awareness of interstitial cystitis, and increasing grants for research on interstitial cystitis. However, the lack of approved drugs is hindering the market growth.

Competitive Analysis

The competitive scenario categorizes companies based on various performance indicators. Some of the factors considered include the financial performance of companies over the past few years, growth strategies, product innovations, new product launches, investments, and growth in market share, among others. Request a Sample

Market Segmentation

Related Reports:

Chronic Obstructive Pulmonary Disease Drugs Market by Product, Distribution Channel and Geography - Forecast and Analysis 2023-2027: The chronic obstructive pulmonary disease drugs market is estimated to grow at a CAGR of 6.09% between 2022 and 2027. The size of the market is forecast to increase by USD 6,654.49 million. The rising prevalence of COPD is notably driving the market growth, although factors such as the high cost of conducting clinical trials in COPD may impede the market growth.

Allergy Immunotherapies Market by Product, Type, and Geography - Forecast and Analysis 2023-2027: The allergy immunotherapies market is estimated to grow at a CAGR of 8.95% between 2022 and 2027. The size of the market is forecast to increase by USD 1,010.37 million. The increasing prevalence of allergies is notably driving the market growth, although factors such as trial failures may impede the market growth.

Technavio's library includes over 17,000+ reports, covering more than 2,000 emerging technologies. Subscribe to our "Basic Plan" at just USD 5,000 and get lifetime access to Technavio Insights

What are the key data covered in this interstitial cystitis (IC) drugs market report?

Interstitial Cystitis Drugs Market Scope

Report Coverage

Details

Page number

160

Base year

2022

Historic period

2017-2021

Forecast period

2023-2027

Growth momentum & CAGR

Accelerate at a CAGR of 5.9%

Market growth 2023-2027

USD 369.58 million

Market structure

Fragmented

YoY growth 2022-2023(%)

5.26

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 35%

Key countries

US, UK, Germany, Japan, and China

Competitive landscape

Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks

Key companies profiled

Allergan, Amneal Pharmaceuticals Inc., Astellas Pharma Inc., Aurobindo Pharma Ltd., Bayer AG, Cadila Healthcare Ltd., Eli Lilly and Co., Hikma Pharmaceuticals Plc, Intas Pharmaceuticals Ltd., Johnson and Johnson, Kyorin Pharmaceutical Co. Ltd., Mission Pharmacal Co., Perrigo Co. Plc, Pfizer Inc., Purdue Pharma LP, Seikagaku Corp., Sun Pharmaceutical Industries Ltd., Taro Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc.

Market dynamics

Parent Market Analysis; Market growth inducers and obstacles; Fast-growing and slow-growing segment analysis for the forecast period

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Browse for Technavio "Health Care" Research Reports

Table of Content

1 Executive Summary

2 Market Landscape

3 Market Sizing

4 Five Forces Analysis

5 Market Segmentation by Type

6 Customer landscape

7 Geographic Landscape

8 Drivers, Challenges, and Trends

9 Vendor Landscape

10 Vendor Analysis

11 Appendix

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

SOURCE Technavio


These press releases may also interest you

at 03:05
Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
Takeda (TSE:4502/NYSE:TAK) announced that its Board of Directors today decided that it will propose a new candidate for independent external director at the 147th Ordinary Meeting of Shareholders on June 28th, 2023. The new candidate, Miki Tsusaka,...

at 03:00
Creative Safety Supply Releases Comprehensive Pharmaceutical Labeling Guide
Creative Safety Supply, a leading provider of industrial safety and labeling solutions, has announced the release of its...

at 03:00
'Teaching kids to brush their teeth,' top tips from the Paso Robles dentist
"Kids start copying their parent's behavior at a very young age and this certainly works in favor of teaching kids to brush their teeth," said Lisa Lu Davis, DMD, the Paso Robles dentist. While it's important to start good oral hygiene as soon as...

at 02:40
Implantica Launches RefluxStoptm in Italy
Implantica AG (publ), a medtech company at the forefront of bringing advanced technology into the body, announces today that the first RefluxStoptm procedures were performed in Italy, a key market where more than 10 percent of the population...

at 02:37
Hansa Biopharma publishes Annual Report 2022
Hansa Biopharma AB "Hansa" (STO TIDM: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announced the release of the Annual Report 2022. Søren Tulstrup, President and CEO of Hansa Biopharma, comments: "2022 was a...

at 02:30
Healthcare Education Solutions Market to grow at a CAGR of 8.53% from 2021 to 2026, Driven by the need to address challenges in the healthcare industry through effective medical training - Technavio
The global healthcare education solutions market size is estimated to grow by USD 6.57 billion from 2021 to 2026, according to Technavio. The market is estimated to grow at a CAGR of 8.53% during the forecast period. Factors such as the need to...

More news about Health...


News published on 30 january 2023 at 21:15 and distributed by: